ZA202405110B - Discernible cell surface protein variants of cd117 for use in cell therapy - Google Patents

Discernible cell surface protein variants of cd117 for use in cell therapy

Info

Publication number
ZA202405110B
ZA202405110B ZA2024/05110A ZA202405110A ZA202405110B ZA 202405110 B ZA202405110 B ZA 202405110B ZA 2024/05110 A ZA2024/05110 A ZA 2024/05110A ZA 202405110 A ZA202405110 A ZA 202405110A ZA 202405110 B ZA202405110 B ZA 202405110B
Authority
ZA
South Africa
Prior art keywords
surface protein
discernible
therapy
protein variants
cell
Prior art date
Application number
ZA2024/05110A
Other languages
English (en)
Inventor
Stefanie Urlinger
Rosalba Lepore
Lukas Jeker
Amélie Wiederkehr
Alessandro Sinopoli
Anna Camus
Lisa Wellinger
Romina Matter-Marone
Original Assignee
Univ Basel
Cimeio Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel, Cimeio Therapeutics Ag filed Critical Univ Basel
Publication of ZA202405110B publication Critical patent/ZA202405110B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA2024/05110A 2021-12-16 2024-06-28 Discernible cell surface protein variants of cd117 for use in cell therapy ZA202405110B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21215028 2021-12-16
EP22164796 2022-03-28
EP22207926 2022-11-16
PCT/EP2022/086452 WO2023111311A1 (en) 2021-12-16 2022-12-16 Discernible cell surface protein variants of cd117 for use in cell therapy

Publications (1)

Publication Number Publication Date
ZA202405110B true ZA202405110B (en) 2025-12-17

Family

ID=84981434

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/05110A ZA202405110B (en) 2021-12-16 2024-06-28 Discernible cell surface protein variants of cd117 for use in cell therapy

Country Status (10)

Country Link
US (1) US20250057951A1 (cg-RX-API-DMAC7.html)
EP (1) EP4448573A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024546996A (cg-RX-API-DMAC7.html)
KR (1) KR20240115920A (cg-RX-API-DMAC7.html)
AU (1) AU2022409748A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240527A1 (cg-RX-API-DMAC7.html)
IL (1) IL313568A (cg-RX-API-DMAC7.html)
MX (1) MX2024007317A (cg-RX-API-DMAC7.html)
WO (1) WO2023111311A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202405110B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4540287A1 (en) * 2022-06-20 2025-04-23 CRISPR Therapeutics AG Chimeric antigen receptor specific to cd117
EP4543469A4 (en) * 2022-06-27 2026-06-03 Beam Therapeutics Inc COMPOSITIONS AND CONDITIONING METHODS OF NON-GENOTOXIC CELLS
EP4551601A1 (en) * 2022-07-07 2025-05-14 Cimeio Therapeutics AG Antibodies targeting cd117
WO2025231071A1 (en) * 2024-05-01 2025-11-06 Beam Therapeutics Inc. Compositions and methods for cell conditioning

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0578774T3 (da) 1991-04-05 1999-04-26 Univ Washington Monoklonale antistoffer mod stamcellefaktor-receptorer
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之c-kit抗體
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
EP3448995A1 (en) 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
US20190365806A1 (en) 2016-11-02 2019-12-05 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
EP3700568A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN113164570B (zh) * 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
JP2022529727A (ja) * 2019-04-24 2022-06-23 マジェンタ セラピューティクス インコーポレイテッド Anti-cd117 とその使用
AU2020336969B2 (en) 2019-08-29 2024-12-05 Beam Therapeutics Inc. Compositions and methods for non-toxic conditioning

Also Published As

Publication number Publication date
WO2023111311A1 (en) 2023-06-22
US20250057951A1 (en) 2025-02-20
JP2024546996A (ja) 2024-12-26
IL313568A (en) 2024-08-01
KR20240115920A (ko) 2024-07-26
AU2022409748A1 (en) 2024-05-23
MX2024007317A (es) 2024-06-26
EP4448573A1 (en) 2024-10-23
CA3240527A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2024007317A (es) Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular.
ZA202405124B (en) Discernible cell surface protein variants of cd45 for use in cell therapy
SG196784A1 (en) Stem cell cultures
WO2019229701A3 (en) Binding molecules against bcma and uses thereof
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
GB2454386A (en) Method for stem cell culture and cells derived therefrom
MX344970B (es) Medio de cultivo celular para la expresion de la proteina adamts.
BR112014031424A2 (pt) tratamento de células pluripotentes
MX2008007286A (es) Ingenieria in vivo de superficie celular.
NZ703148A (en) Modified factor x polypeptides and uses thereof
DE60103052D1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
WO2009077134A3 (en) Use of rna for reprogramming somatic cells
EP2603227A4 (en) IMPROVED HEMATOPOETIC TRIBE AND PRECURSOR CELL THERAPY
MX337041B (es) Cepas y metodos para mejorar la salud y/o desempeño de los rumiantes.
MX2019007890A (es) Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
AU2017241807A1 (en) Medium, methods, cells and secreted factors for stem cell culture and therapy
PH12014501175A1 (en) Medium composition for rejuvenating stem cells
DOP2014000294A (es) Purificación de iduronato 2 sulfatasa
WO2011096728A3 (en) Method for proliferating stem cells by activating c-met/hgf signaling and notch signaling
CL2022001655A1 (es) Variantes diseñadas de la alfa-glucosidasa ácida.
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
MX2021003567A (es) Métodos y composiciones para aumentar la expresión de proteínas y/o tratar un trastorno por haploinsuficiencia.
WO2021101273A3 (ko) 조절 t 세포 배양용 조성물 및 이의 용도
WO2011142832A3 (en) Stem cells derived under low oxygen conditions
WO2022046935A3 (en) Methods and compositions for treating glioblastoma